1 Ocak 2018 Dergi makalesi Açık Erişim

Gorgulu, G.; Cicek, M. B.; Dede, B.

Dublin Core

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Gorgulu, G.</dc:creator>
  <dc:creator>Cicek, M. B.</dc:creator>
  <dc:creator>Dede, B.</dc:creator>
  <dc:date>2018-01-01</dc:date>
  <dc:description>A novel ligand, N, N ''-(4-methyl-1,2-phenylene)bis(2-(biphenyl-4-yl)-N'-hydroxy-2-oxoacetimidamide) (H2L) with its Cu(II) and Mn(II) complexes were synthesized in this study. All compounds synthesized were also characterized by H-1- and C-13-NMR, the Fourier transform infrared, elemental analysis, inductively coupled plasma optical emission spectrometry, molar conductivity, magnetic susceptibility measurements and thermogravimetric analysis. Vascular endothelial growth factor-2 (VEGFR-2) and cyclooxygenase-2 (COX-2) inhibition is often used as a parameter for being a potent anticancer agent in docking studies. For this purpose, synthesized and characterized ligand was investigated by molecular docking study to test its inhibitory effect against angiogenic factors VEGFR-2 and COX-2.</dc:description>
  <dc:identifier>https://aperta.ulakbim.gov.trrecord/32521</dc:identifier>
  <dc:identifier>oai:zenodo.org:32521</dc:identifier>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>http://www.opendefinition.org/licenses/cc-by</dc:rights>
  <dc:source>ACTA PHYSICA POLONICA A 133(2) 250-255</dc:source>
  <dc:title>Novel Aminoketooxime Ligand and Its Cu(II) and Mn(II) Complexes: Synthesis, Characterization and Molecular Docking Studies</dc:title>
  <dc:type>info:eu-repo/semantics/article</dc:type>
  <dc:type>publication-article</dc:type>
</oai_dc:dc>